Samrat Pharmachem Limited (BOM:530125)

Market Cap	604.50M -43.0%
Revenue (ttm)	2.89B -2.8%
Net Income	-16.75M
EPS	-5.42
Shares Out	3.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (0.51%)
Ex-Dividend Date	Sep 18, 2025

Volume	2,071
Average Volume	2,553
Open	212.50
Previous Close	205.05
Day's Range	195.10 - 212.50
52-Week Range	195.10 - 425.00
Beta	-0.51
RSI	42.48
Earnings Date	May 30, 2026

About Samrat Pharmachem

Samrat Pharmachem Limited engages in the manufacture and sale of pharmaceutical chemicals in India. It offers 3-5-di iodosalicylic acid, ammonium iodide, cadmium iodide, calcium iodate, clioquinol, copper iodide, ethyl iodide, ethylenediamine dihydroiodide, hydroiodic acid, iodine, iodine monochloride, iodoquinol, methyl iodide, n-iodo succinimide, periodic acid, potassium iodate and iodide, potassium metaper iodate, povidone iodine, sodium iodate and iodide, and sodium metaper iodate. The company serves the agrochemical, animal feed, chemical,...

• Industry: Industrial Inorganic Chemicals
• Founded: 1992
• Employees: 28
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530125

Financial Performance

In fiscal year 2025, Samrat Pharmachem's revenue was 2.86 billion, an increase of 1.52% compared to the previous year's 2.82 billion. Earnings were 71.12 million, an increase of 228.87%.